Alembic Pharmaceuticals Ltd

Stage 2 · Advancing · week 9Setup 3.5 WatchEven +0.8

As of 16 Oct 2026, Alembic Pharmaceuticals is in Stage 2 — advancing, the uptrend phase, in week 9 (since 13 Aug 2026). It closed at ₹789, 17.8% below its 52-week high and above its 200-day average, which is falling. In Health Care, 40.0% of stocks are in Stage 2.

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. More about the company

₹789.5
-0.40% today
₹15,518 Cr · Mid cap
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dPharmaceuticals 49.6%-2.5 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

3.5 Watch

Momentum

Steady

Edge

Even +0.8

Setup-score rank among Stage 2 peers: #51 of 59 in Pharmaceuticals · #61 of 70 in Health Care

Is APLLTD early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-17.8%
₹646.6 lo₹960.7 hi
17.8% below 52W high — deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 9
1w13w26w
Week 9 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
1.1%
200 DMA: ₹780.6 · sloping down
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.88x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
→
MA20 flat · -0.5% vs MA50 +0.3%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-4.3%
3M
-4.3%
6M
+5.5%
YTD
-7.5%
1Y
-15.2%
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
This stock ranks #61 of 66 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
49.6%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #51 of 56 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 15w
S2 18w
S2 14w
S4 15w
S3 14w
S4 25w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 15w → S3 10w → S2 18w → S3 10w → S2 14w → S3 12w → S4 15w → S1 9w → S2 5w → S3 14w → S4 25w → S1 11w → S2 9w current
Total tracked: 168 weeks across 13 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-08-13
4 appearances in last 60 days. First seen: 2024-01-12.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S2
Wk 9 · Vol 0.88x
2026-10-15S2
Wk 9 · Vol 0.44x
2026-10-14S2
Wk 9 · Vol 0.40x
2026-10-13S2
Wk 9 · Vol 0.40x
2026-10-12S2
Wk 9 · Vol 0.63x
2026-10-09S2
Wk 8 · Vol 1.08x
2026-10-08S2
Wk 8 · Vol 1.00x
2026-10-07S2
Wk 8 · Vol 0.80x
2026-10-06S2
Wk 8 · Vol 0.85x
2026-10-05S2
Wk 8 · Vol 1.73x
2026-10-01S2
Wk 7 · Vol 2.08x
2026-09-30S2
Wk 7 · Vol 1.74x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹823.6
200 DMA
₹780.6
52W High
₹960.7
52W Low
₹646.6
5D Low
₹789.1
Resistance levels (recent highs)
20d High
₹863.8
60d High
₹863.8
120d High
₹863.8
250d High
₹960.7
Next resistance
+9.4%
to 20d High
Ask the Market AI about APLLTDAsk →
P/E (TTM)
22.0
Forward 15.6
Earnings Growth (YoY)
+29.2%
Revenue +4.4%
ROE
+12.4%
Profit margin +9.2%
Dividend Yield
1.45%
P/B 2.6
About this companyHealth Care· Pharmaceuticals

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.